<DOC>
	<DOCNO>NCT00365768</DOCNO>
	<brief_summary>RATIONALE : Glutamine may help lessen neuropathy cause chemotherapy . It yet know whether glutamine effective placebo treat neuropathy cause vincristine . PURPOSE : This randomized phase II trial study glutamine see well work compare placebo treat neuropathy cause vincristine young patient lymphoma , leukemia , solid tumor .</brief_summary>
	<brief_title>Glutamine Treating Neuropathy Caused Vincristine Young Patients With Lymphoma , Leukemia , Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine incidence vincristine-induced peripheral neuropathy pediatric patient lymphoma , leukemia , solid tumor . Secondary - Compare safety glutamine v placebo patient . - Compare efficacy glutamine v placebo reduce progression and/or resolution vincristine-induced peripheral neuropathy patient . - Compare effect glutamine supplementation v placebo chemotherapy-related toxicity patient . - Compare effect glutamine v placebo measure quality life patient . - Compare effect glutamine supplementation v placebo serum nerve growth factor glutamine level patient . - Determine effect glutamine vincristine-mediated antitumor efficacy vitro . OUTLINE : This randomize , double-blind , placebo-controlled , pilot study . Patients randomize 1 2 treatment arm . - Arm I : Beginning 1 week administration vincristine chemotherapy , patient receive oral glutamine twice daily day 1-21 . - Arm II : Beginning 1 week administration vincristine chemotherapy , patient receive oral placebo twice daily day 1-21 . Patients arm undergo neuropsychological clinical neurological assessment , blood collection serum marker ( e.g. , serum glutamine nerve growth factor ) analysis , quality life assessment day 1 , 21 , 42 . After completion study treatment , patient follow additional 21 day . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients age 5 21 year old . Patients demonstrate ability complete assessment instrument baseline . Patients diagnose leukemia solid tumor expect receive cumulative dose &gt; = 6mg/m2 vincristine , &gt; 6mg individual vincristine dos cap 2mg accord primary cancer treatment protocol , 30week period . Patients primary CNS tumor medulloblastoma patient CNS metastasis . Patients recurrent disease . Patients Grade II , III IV neurological status NCI CTC ( Ver . 3.0 ) clinical exam . Patients already receive &gt; 8mg/m2 vincristine , &gt; 8mg individual vincristine dos cap 2mg accord primary cancer treatment protocol , course therapy time consent . Patients hepatic encephalopathy hyperammonemia . Patients focally abnormal neurologic exam .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I Wilms tumor</keyword>
	<keyword>stage II Wilms tumor</keyword>
	<keyword>stage III Wilms tumor</keyword>
	<keyword>stage IV Wilms tumor</keyword>
	<keyword>stage V Wilms tumor</keyword>
	<keyword>childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>localize Ewing sarcoma/PNET</keyword>
	<keyword>metastatic Ewing sarcoma/PNET</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>peripheral neuropathy</keyword>
</DOC>